BARCELONA, Spain I January 04, 2024 I La Merie Publishing released its newest product reviewing the pipeline of anti-nectin-4 immunotherapeutics on the market and in R&D:
Nectin-4-Targeted Immunotherapy Pipeline Review
Target: Nectin-4; Nectin cell adhesion molecule-4
Product Category: Antibody; Peptide; Cells
This product provides basic information on immunotherapeutics on the market and in R&D targeting nectin-4.
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
- Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for immunotherapeutics targeting nectin-4 (prerequisite: access to internet).
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
The cell surface adhesion protein Nectin-4 is a cancer associated antigen over-expressed in many solid tumor types with limited expression in normal tissues. Nectin-4 is closely related to the progression and poor prognosis of malignant tumors.
Enfortumab Vedotin (EV) is the first nectin-4-targeting antibody-drug conjugate approved by the US FDA for the treatment of advanced urothelial carcinoma. Thereby, nectin-4 has become a clinically validated and commercially successful cancer target. However, inadequate efficacy has limited progress in the treatment of other solid tumors with EV. Furthermore, side effects caused by EV frequently result in dose reduction and/or treatment termination.
Thus, the limitations of EV provides a window of opportunity for novel drug modalities targeting nectin-4 with the promise to improve efficacy and safety.
The report “Nectin-4-Targeted Immunotherapy Pipeline Review” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/nectin-4-targeted-immunotherapy-pipeline-review/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 229
BARCELONA, Spain I January 04, 2024 I La Merie Publishing released its newest product reviewing the pipeline of anti-nectin-4 immunotherapeutics on the market and in R&D:
Nectin-4-Targeted Immunotherapy Pipeline Review
Target: Nectin-4; Nectin cell adhesion molecule-4
Product Category: Antibody; Peptide; Cells
This product provides basic information on immunotherapeutics on the market and in R&D targeting nectin-4.
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
- Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to La Merie Publishing’s database for immunotherapeutics targeting nectin-4 (prerequisite: access to internet).
This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.
The cell surface adhesion protein Nectin-4 is a cancer associated antigen over-expressed in many solid tumor types with limited expression in normal tissues. Nectin-4 is closely related to the progression and poor prognosis of malignant tumors.
Enfortumab Vedotin (EV) is the first nectin-4-targeting antibody-drug conjugate approved by the US FDA for the treatment of advanced urothelial carcinoma. Thereby, nectin-4 has become a clinically validated and commercially successful cancer target. However, inadequate efficacy has limited progress in the treatment of other solid tumors with EV. Furthermore, side effects caused by EV frequently result in dose reduction and/or treatment termination.
Thus, the limitations of EV provides a window of opportunity for novel drug modalities targeting nectin-4 with the promise to improve efficacy and safety.
The report “Nectin-4-Targeted Immunotherapy Pipeline Review” can be acquired at La Merie Publishing’s online store: https://lamerie.com/report/nectin-4-targeted-immunotherapy-pipeline-review/
About La Merie Publishing
La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.
La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.
SOURCE: La Merie Publishing
Post Views: 229
